TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 4726.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Mycenax Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Mycenax Biotech Inc.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -NT$0.28. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Mycenax Biotech Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the United States. The company cultivates a diverse portfolio of advanced biological therapeutics and components. This includes monoclonal antibodies, bi-specific antibodies, Fc-fusion proteins, recombinant proteins, peptides, non-toxic protein conjugates, antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), in addition to plasmids and DNA vaccines. Beyond product innovation, Mycenax offers a comprehensive suite of process development solutions. These encompass the establishment of production cell lines, optimization of upstream and downstream processes, industrial scale-up, formulation science, and the creation of analytical methods. The firm also provides in-house analytical testing, Good Manufacturing Practice (GMP)-compliant manufacturing services for drug substances and finished products, and cell banking, all underpinned by its specialized manufacturing technologies. Established in 2001, Mycenax Biotech Inc. is headquartered in Zhubei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 13, 2025 | -NT$0.40-44.05% vs estimate | NT$193.99M-37.42% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -NT$0.71-22.41% vs estimate | NT$209.13M-20.18% vs estimate |
|---|
| Q2 2024 | Aug 9, 2024 | -NT$0.49+22.22% vs estimate | NT$200.61M+12.7% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$100.00-NT$3.50 (-3.38%)
CHO Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.66% below the high.
NT$47.80-NT$1.20 (-2.45%)
EirGenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.3% below the high.
NT$39.55-NT$0.50 (-1.25%)
Locus Cell Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.24% below the high.
NT$12.80-NT$0.55 (-4.12%)
Acepodia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.44% below the high.
NT$20.00-NT$0.50 (-2.44%)
Abnova (Taiwan) Corporation’s quoted price sits in the lower half of its reported 52-week range, 31.39% below the high.
